Cadonilimab: First Approval

2022/08/01 by Susan J. Keam · 28 citations
Medicine · #Cancer Immunotherapy and Biomarkers #Esophageal Cancer Research and Treatment #Bladder and Urothelial Cancer Treatments

paper · doi:10.1007/s40265-022-01761-9

Cited by

• Overview of tumor immunotherapy based on approved drugs
• T cells in health and disease
• Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy
• Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data. [europepmc]
• Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. [europepmc]
• MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. [europepmc]
• Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials. [europepmc]
• Advances in immune checkpoint inhibitors induced-cardiotoxicity. [europepmc]
• Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. [europepmc]
• A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. [europepmc]
• Antibody-based cancer immunotherapy by targeting regulatory T cells. [europepmc]
• Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. [europepmc]
• T cells in health and disease. [europepmc]
• Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy. [europepmc]
• The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge. [europepmc]
• Hot and cold tumors: Immunological features and the therapeutic strategies. [europepmc]
• A pivotal decade for bispecific antibodies? [europepmc]
• The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling. [europepmc]
• Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy. [europepmc]
• A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. [europepmc]
• Signaling pathways in liver cancer: pathogenesis and targeted therapy. [europepmc]
• The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study. [europepmc]
• Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study. [europepmc]
• Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies. [europepmc]
• Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. [europepmc]
• Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy. [europepmc]
• Bispecific Antibodies in Solid Tumors: Advances and Challenges. [europepmc]
• T cells in cancer: mechanistic insights and therapeutic advances. [europepmc]